Management of chronic myeloid leukemia in chronic phase with autologous stem cell transplantation and alpha-2 interferon: Cytogenetic and clinical results

Giuliana Alimena, Giovanna Meloni, M. Rosaria De Cuia, M. Beatrice Rondinelli, Francesco Lo Coco, Enrico Montefusco, Marco Mancini, Rita Pinto, Mauro Nanni, Michele Cedrone, Paolo De Fabritiis, Franco Mandelli

Research output: Contribution to journalArticlepeer-review

Abstract

Forty-eight patients with chronic myeloid leukemia (CML) in chronic phase (CP) were treated by autologous stem cells transplantation (ASCT) and α Interferon (IFN) with three approaches: 1) ASCT at diagnosis followed by IFN, 2) ASCT post IFN with cells collected after an interval from IFN discontinuance, followed by IFN, 3) ASCT in patients selected by cytoconversion obtained with IFN, performed soon after IFN discontinuance. Following ASCT, a major karyotype response (more than 65% Ph1 negative cells, MKR) was observed at least once in 40% 53% and 83% of patients from the three groups, respectively. At last follow-ups (median 39, 40 and 21 months, respectively) 19% 13% and 67% of patients still present a MKR with 2 patients from group 1 and 4 patients from group 3 being 100% Ph1 negative. Projected survival from diagnosis is 77% at 52 months for patients from group 1 and 47% at 75 months for patients from group 2. Present data indicate that 1) IFN can stabilize results obtained with ASCT, 2) ASCT can potentiate responses to IFN, 3) combined ASCT and IFN can improve survival. Longer follow-up of patients and randomized studies are required to define the real impact on disease outcome by these treatment approaches.

Original languageEnglish
Pages (from-to)281-291
Number of pages11
JournalLeukemia and Lymphoma
Volume11
Issue numbers1
DOIs
Publication statusPublished - 1993

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Management of chronic myeloid leukemia in chronic phase with autologous stem cell transplantation and alpha-2 interferon: Cytogenetic and clinical results'. Together they form a unique fingerprint.

Cite this